The efficacy of sirolimus in the treatment of patients with refractory uveitis

British Journal of Ophthalmology

Volumn 89, Issue 6, 2005, Pages 666-669

  Shanmuganathan, V A ^a   Casely, E M ^a   Raj, D ^b   Powell, R J ^a   Joseph, A ^a   Amoaku, W M ^a   Dua, H S ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACETATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ABDOMINAL PAIN; ACNE; ADULT; ARTICLE; BREAST DISEASE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENCY; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; EYE INFLAMMATION; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER DYSFUNCTION; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; RASH; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; SCLERODERMA; SEBORRHEIC DERMATITIS; SIDE EFFECT; SKIN TOXICITY; SYMPTOMATOLOGY; SYSTEMIC THERAPY; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

ADULT; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PREDNISOLONE; RECURRENCE; SEVERITY OF ILLNESS INDEX; SIROLIMUS; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 20344366299     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2004.048199     Document Type: Article

References (20)

1. Rathava A, Suttorp-van Schulten MS, Frits Treffers W, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-6.
2. Stanbury RM, Graham EM. Systemic corticosteroid therapy-side effects and their management. Br J Ophthalmol 1998;82:704-8.
3. Ben Ezra D, Forrester JV, Nussenblat RB, et al. Uveitis scoring system. Berlin: Springer-Verlag, 1991:1-13.
4. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28:721-6.
5. Dupont P, Warrens AN. The evolving role of sirolimus in renal transplantation. Q J Med 2003;96:401-9.
6. Radovancevic B, Vrtovec B. Sirolimus therapy in cardiac transplantation. Transplant Proc 2003;35(Suppl):171S-176S.
7. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenasis in a native coronary artery. N Engl J Med 2003;349:1315-23.
8. Gregory CR, Huie P, Shorthouse R, et al. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation 1993;55:1409-18.
9. Kirken RA, Wang YL. Molecular actions of sirolimus: sirolimus and mTor. Transplant Proc 2003;35(Suppl):227S-230S.
10. Aagaard-Tillery KM, Jelinek DF. Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol 1994;156:493-507.
11. Ikeda E, Hikita N, Eto K, et al. Tacrolimus-rapamycin combination therapy for experimental autoimmune uveoretinitis. Jpn J Ophtholmol 1997;41:396-402.
12. Martin DF, DeBarge LR, Nussenblatt RB, et al. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uvearetinitis. J Immunol 1995;154:922-7.
13. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 1999;162:2775-84.
14. Olsen TW, Benegas NM, Joplin AC, et al. Rapamycin inhibits corneal allograft rejection and neovascularization. Arch Ophthalmol 1994;112:1471-5.
15. Guba M, Von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
16. Mosterson R, Leikis M, Perkovic V, et al. Sirolimus: a single center experience in combination with calcineurin inhibitors. Transplant Proc 2003;35(Suppl):99S-104S.
17. Lau CH, Comer M, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol 2003;31:487-91.
18. Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003;110:786-9.
19. Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003;110:1449-53.
20. Dick AD, Meyer P, James T, et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000;84:107-9.